Nvidia’s Record $5 Trillion Surge: AI Mega-Deals Propel NVDA Stock – Is $300 Next?
13 November 2025
2 mins read

Nvidia Stock Today (Nov. 13, 2025): Mexico “$1B” Data-Center Claim Denied, SoftBank Exit Still Looms, Earnings Next Week

Nvidia (NASDAQ: NVDA) starts Thursday with a tidy calendar of catalysts and one clear headline: the company denied it’s investing $1 billion to build a “green” AI data center in northern Mexico—walking back a claim made hours earlier by Nuevo León’s governor. The reversal lands just days before Nvidia’s Nov. 19 earnings and alongside lingering market chatter about SoftBank’s sale of its entire NVDA stake last month. 1


Key takeaways

  • Mexico headline clarified: Nvidia stated it “does not have financial investment plans in Nuevo León,” contradicting the governor’s video announcement. Local officials later suggested a separate firm would fund a project that uses Nvidia technology, not Nvidia capital. 1
  • Price snapshot: NVDA last closed at $193.80 on Wednesday (Nov. 12). Early pricing hovered near that level around 01:15 UTC today. Volatility this week has been notable: +5.8% Monday, −3.0% Tuesday. 2
  • Context still in play: SoftBank’s $5.8B sale of its Nvidia stake (publicly disclosed this week) continues to color sentiment ahead of earnings. 3
  • Policy overhang: The U.S. move to block sales of scaled‑down AI chips to China and Jensen Huang’s recent remarks about no active discussions to sell Blackwell into China remain medium‑term watch items. 4
  • Earnings on deck (Nov. 19): Street expectations cluster around ~$55–$56B in revenue and ~$1.23–$1.29 EPS for fiscal Q3 (FY2026), with focus on Blackwell supply, data‑center mix, and export constraints. 5

What changed today

Nvidia denies $1B Mexico project after governor’s claim

In a swift reversal cycle, reports that Nvidia would invest $1B to build a new AI data center in Nuevo León were retracted. Nvidia told Reuters the company has no financial investment plans in the state; subsequent coverage clarified that any local facility would rely on Nvidia technology but not Nvidia funding. The episode appears immaterial to capex near‑term but it matters for narrative risk—investors are particularly sensitive to large, capital‑heavy headlines ahead of next week’s print. 1


NVDA price check and recent tape action

  • Last close (Nov. 12):$193.80
  • Early Thursday (around 01:15 UTC): ~$193.80
  • This week’s swing:+5.79% Monday, then −2.96% Tuesday, reflecting broader AI volatility after policy headlines and positioning into earnings. 2

Note: Precise intraday levels will evolve once regular U.S. trading begins; the range above reflects official close and early indicative pricing.


The setup into earnings (Nov. 19)

Analysts broadly expect another outsized quarter, with revenue estimates clustering around $55–$56B and EPS around $1.23–$1.29. The call’s focal points are clear:

  1. Blackwell rollout & supply: Any fresh detail on B200/GB200 availability and lead times will drive data‑center revenue visibility into 2026. 6
  2. Customer mix & demand durability: Watch hyperscaler deployment cadence and enterprise adoption signals. UBS, for example, remains constructive into the print. 7
  3. Export policy impacts: After last week’s reports that the U.S. will block even scaled‑down AI chips to China, investors want clarity on long‑term exposure (Nvidia has recently emphasized minimal current China contribution to data‑center compute). 4

Macro and sentiment context to keep in mind

  • SoftBank’s exit: The Japanese group sold its entire Nvidia stake (~$5.8B), a move markets read as a liquidity and strategy pivot toward other AI bets. NVDA’s reaction was modest but the headline feeds the “is AI peaking?” debate into earnings week. 3
  • Valuation milestone backdrop: Nvidia recently crossed the $5 trillion market‑cap threshold—useful context when gauging how much perfection is priced in. 8

Bottom line for Nov. 13, 2025

Today’s real development is clarity, not capital: Nvidia isn’t spending $1B on a Mexico data center, despite early claims. With that noise addressed, the narrative snaps back to earnings—specifically, Blackwell timing, data‑center demand, and policy risk. Near‑term price action will likely track incremental datapoints on those three pillars more than local project rumors. 1


Sources

Reuters; Channel NewsAsia; Yahoo Finance; Barron’s; Economic Times; Investing.com; Nvidia newsroom and product pages. Key articles cited inline. 1


Editorial note: This article focuses on developments dated Nov. 13, 2025 and the immediately relevant context that frames today’s trading.

https://youtube.com/watch?v=oaqv-LP9ed0

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Ultimate 2025 Showdown: iOS vs Android vs HarmonyOS — Which Mobile OS Reigns Supreme?
Previous Story

OpenAI Launches GPT‑5.1: Smarter, Warmer ChatGPT With New Personalities and Faster Reasoning — Rolling Out Today (Nov 12, 2025)

Baidu unveils M100 & M300 AI chips and ‘natively multimodal’ ERNIE 5.0 at Baidu World 2025, plus new ‘Tianchi’ supernodes
Next Story

Baidu unveils M100 & M300 AI chips and ‘natively multimodal’ ERNIE 5.0 at Baidu World 2025, plus new ‘Tianchi’ supernodes

Go toTop